BRAF V600E

Where the papers sit

11 papers from the last 6 months study BRAF V600E directly · updated from PubMed 12 Oct 2026

• BRAF-Driven Cancer Therapy

  BRAF-directed care is expanding from melanoma into rare histiocytic and craniopharyngioma settings. BRAF/MEK inhibition is paired with molecular pathology and droplet digital PCR to select patients and track circulating tumour DNA. Mechanistic work on ICMT–INPP5E membrane targeting explains BRAFV600E-driven growth. Sequence-driven inhibitor discovery aims to widen options beyond established BRAF/MEK inhibitors.

  5 papers · 45.5%

• MAPK-Targeted Cancer Therapy

  MAPK-directed treatment in anaplastic thyroid cancer centers on molecular assessment and strategies to overcome innate and acquired resistance. Liquid biopsy offers a route to assess and monitor BRAF V600E, while new pyrimidinopyrimidine compounds seek more potent B-RAF inhibition. Network-based drug repurposing and transcriptional signatures broaden the search beyond conventional inhibitors, including melanoma applications. Durable control remains limited by MAPK escape mechanisms, leaving combination design and clinical validation open.

  4 papers · 36.4%

• Early-Onset and Mismatch-Repair Colorectal Cancer

  Colorectal cancer is being partitioned by age at diagnosis and mismatch-repair status rather than treated as a single entity. Disease diagnosed before 35 is examined as a potentially distinct early-onset subset, with odds ratios framing its clinical differences. Molecular lineages of sporadic mismatch-repair-deficient tumors add heterogeneity within dMMR disease. The shared priority is sharper risk definition and molecular classification, not a single treatment direction.

  2 papers · 18.2%